Advertisement

Topics

MS patients in England will have access to Mavenclad thanks to commercial agreement

07:06 EST 9 Nov 2017 | EPM Magazine

Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today.

Original Article: MS patients in England will have access to Mavenclad thanks to commercial agreement

NEXT ARTICLE

More From BioPortfolio on "MS patients in England will have access to Mavenclad thanks to commercial agreement"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...